Kiniksa Pharmaceuticals International (KNSA) Free Cash Flow (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Free Cash Flow for 10 consecutive years, with $46.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Free Cash Flow rose 66.07% year-over-year to $46.5 million; the trailing twelve-month figure through Jun 2026 stood at $180.6 million (up 172.03% YoY), and the FY2025 full-year result was $136.4 million, up 755.06% from the prior year.
• Free Cash Flow eased to $46.5 million in Q2 2026 per KNSA's latest filing, from $50.0 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $62.1 million in Q3 2022 and bottomed at -$34.1 million in Q1 2022.
• Historically, Free Cash Flow has averaged $15.3 million across 5 years, with a median of $11.0 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Free Cash Flow slumped 113.22% in 2024, then soared 3799.04% in 2025.
• Over 5 years, Free Cash Flow stood at -$11.8 million in 2022, then jumped by 148.4% to $5.7 million in 2023, then surged by 183.48% to $16.2 million in 2024, then jumped by 210.81% to $50.5 million in 2025, then retreated by 7.85% to $46.5 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered $46.5 million, $50.0 million, and $50.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.